SCHEMBL19974170

SCHEMBL19974170

CC(C)(C)OC(=O)NNC(=O)/C=C/C(=O)Nc1nccs1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.56
MAPT P10636 2/20 0.56
HTT P42858 2/20 0.56
RAB9A P51151 7/20 0.54
METAP1 P53582 1/20 0.52
SMN1; SMN2 Q16637 7/20 0.49
NPC1 O15118 6/20 0.49
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 3/20 0.49
NFKB1 P19838 2/20 0.49
NFKB2 Q00653 2/20 0.49
RELA Q04206 2/20 0.49
TP53 P04637 2/20 0.49
KMT2A Q03164 2/20 0.49
HPGD P15428 2/20 0.47
GAA P10253 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.44
POLB P06746 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14720 0.82 METAP1 (0.66) MAPTHTTRAB9AMETAP1SMN1; SMN2
Formic Acid SCHEMBL27988165 0.80 METAP1 (0.60) LMNAMAPTHTTRAB9AMETAP1
SCHEMBL27567716 0.79 METAP1 (0.53) LMNAMAPTHTTRAB9AMETAP1
SCHEMBL19974517 0.79 L3MBTL1 (0.73) LMNAMAPTHTTRAB9ASMN1; SMN2
SCHEMBL23657159 0.76 LMNA (0.74) LMNAMAPTHTTRAB9ASMN1; SMN2
SCHEMBL17844701 0.74 RAB9A (0.79) LMNAMAPTHTTRAB9ASMN1; SMN2
SCHEMBL32690316 0.74 RAB9A (0.66) LMNAMAPTHTTRAB9ASMN1; SMN2
SCHEMBL19974151 0.74 RAB9A (0.66) LMNAMAPTHTTRAB9ASMN1; SMN2
SCHEMBL19974134 0.74 RAB9A (0.66) LMNAMAPTHTTRAB9ASMN1; SMN2
SCHEMBL30271553 0.73 RAB9A (0.63) LMNAMAPTHTTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3512602-B1 INHIBITORS OF HEAT SHOCK FACTORS (HSF) AND USES THEREOF HSF PHARMACEUTICALS (CH) 2024-03-27 EP disclosed
US-11597708-B2 Inhibitors of heat shock factors and uses thereof HSF PHARMACEUTICALS SA (CH) 2023-03-07 US disclosed
US-20210221778-A1 Inhibitors of heat shock factors and uses thereof HSF PHARMACEUTICALS SA (CH) 2021-07-22 US disclosed
EP-3512602-A2 INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF HSF Pharmaceuticals (CH) 2019-07-24 EP disclosed
WO-2018050656-A2 INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF HSF PHARMACEUTICALS (CH) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597708-B2 Inhibitors of heat shock factors and uses thereof HSF1, HSP90AB2P, HSP90AB1 LMNA 3549/4885MAPT 2930/4885HTT 1981/4885
US-20210221778-A1 Inhibitors of heat shock factors and uses thereof HSF1, HSP90AB2P, HSP90AB1 LMNA 3549/4885MAPT 2930/4885HTT 1981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.